FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
Director/PDMR Shareholding
26 March 2018 15:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
AstraZeneca
PLC (the Company) announces that, on 23 March 2018, certain Persons
Discharging Managerial Responsibilities of the Company (PDMRs) were
granted awards of the Company's ordinary shares of $0.25 each
(Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus
Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
PDMR
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
Pascal
Soriot
|
13,157
|
128,889
|
£48.53
|
Marc
Dunoyer
|
7,037
|
61,240
|
£48.53
|
The
AZDBP award represents the portion of each PDMR's annual bonus for
2017 that they are required to defer into shares. The Ordinary
Shares granted under the AZDBP are subject to a three-year holding
period and are due to vest on the third anniversary of
grant.
The
AZPSP award is subject to a combination of performance measures
focused on scientific, commercial and financial performance
assessed over a three-year performance period (1 January 2018 to 31
December 2020). The Ordinary Shares granted under the AZPSP are
subject to a two-year holding period following the performance
period, and are due to vest on the fifth anniversary of
grant.
Details
of the performance measures attached to the AZPSP award can be
found in the Directors' Remuneration Report within the AstraZeneca
Annual Report and Form 20-F Information 2017, which is available on
the Company's website at www.astrazeneca.com/annualreport2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. The Company also is selectively active
in the areas of autoimmunity, neuroscience and infection.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media Relations
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203 749 5638
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
Gonzalo
Viña
|
UK/Global
|
+44 203 749 5916
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
Investor Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
Craig
Marks
|
Finance; Fixed Income; M&A
|
+44 7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
Mitchell
Chan
|
Oncology; Other
|
+1 240 477 3771
|
Christer
Gruvris
|
Brilinta;
Diabetes
|
+44 203 749 5711
|
Nick
Stone
|
Respiratory; Renal
|
+44 203 749 5716
|
US
toll free
|
|
+1 866 381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
26 March
2018
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|